Synthetic Biology And The Computerization Of Drug Development
Executive Summary
Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.
You may also be interested in...
Can Artificial Intelligence Help Find Better Medicines?
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.
Cell Design Labs Envisions Robot Control of Tomorrow's CAR-T Therapies
Emerging Company Profile: San Francisco startup aligned with Kite Pharma believes T-cells may be programmed to reversibly activate and deactivate, greatly improving specificity, efficacy and safety of chimeric antigen receptor T-cell therapies.
Juno ROCKETs On Fast Clinical Hold Resolution
The FDA lifted a clinical hold on the Phase II ROCKET clinical trial for Juno's lead CAR-T therapy candidate JCAR015 less than a week after it was instituted, allowing the company to proceed without using fludarabine in a pre-conditioning chemotherapy regimen.